Diroximel fumarate is a prodrug form of monomethyl fumarate .1 It undergoes esterase cleavage in the gut to release monomethyl fumarate. Formulations containing diroximel fumarate have been used in the treatment of relapsing-remitting multiple sclerosis.
1.Naismith, R.T., Wolinsky, J.S., Wundes, A., et al.Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 studyMult. Scler.(2019)
















